Hepcidin Therapeutics

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2018 Nov 25

PMID 30469435

Citations 45

Authors

Angeliki Katsarou

Kostas Pantopoulos

Affiliations

Soon will be listed here.

Abstract

Hepcidin is a key hormonal regulator of systemic iron homeostasis and its expression is induced by iron or inflammatory stimuli. Genetic defects in iron signaling to hepcidin lead to "hepcidinopathies" ranging from hereditary hemochromatosis to iron-refractory iron deficiency anemia, which are disorders caused by hepcidin deficiency or excess, respectively. Moreover, dysregulation of hepcidin is a pathogenic cofactor in iron-loading anemias with ineffective erythropoiesis and in anemia of inflammation. Experiments with preclinical animal models provided evidence that restoration of appropriate hepcidin levels can be used for the treatment of these conditions. This fueled the rapidly growing field of hepcidin therapeutics. Several hepcidin agonists and antagonists, as well as inducers and inhibitors of hepcidin expression have been identified to date. Some of them were further developed and are currently being evaluated in clinical trials. This review summarizes the state of the art.

Citing Articles

Hepatic Iron Overload and Hepatocellular Carcinoma: New Insights into Pathophysiological Mechanisms and Therapeutic Approaches.

Chatzikalil E, Arvanitakis K, Kalopitas G, Florentin M, Germanidis G, Koufakis T Cancers (Basel). 2025; 17(3).

PMID: 39941760 PMC: 11815926. DOI: 10.3390/cancers17030392.

Iron metabolism in rheumatic diseases.

Givian A, Azizan A, Jamshidi A, Mahmoudi M, Farhadi E J Transl Autoimmun. 2025; 10:100267.

PMID: 39867458 PMC: 11763848. DOI: 10.1016/j.jtauto.2025.100267.

Hepcidin Is a Valuable Therapeutic Target for Colorectal Cancer.

Frascatani R, Colella M, Monteleone G Cancers (Basel). 2024; 16(23).

PMID: 39682254 PMC: 11640601. DOI: 10.3390/cancers16234068.

Metabolic dysregulation in myelodysplastic neoplasm: impact on pathogenesis and potential therapeutic targets.

Zhou H, Xiang W, Zhou G, Rodrigues-Lima F, Guidez F, Wang L Med Oncol. 2024; 42(1):23.

PMID: 39644425 DOI: 10.1007/s12032-024-02575-3.

Iron homeostasis and ferroptosis in human diseases: mechanisms and therapeutic prospects.

Ru Q, Li Y, Chen L, Wu Y, Min J, Wang F Signal Transduct Target Ther. 2024; 9(1):271.

PMID: 39396974 PMC: 11486532. DOI: 10.1038/s41392-024-01969-z.

References

Aisen P, Enns C, Wessling-Resnick M . Chemistry and biology of eukaryotic iron metabolism. Int J Biochem Cell Biol. 2001; 33(10):940-59. DOI: 10.1016/s1357-2725(01)00063-2. View

Hunter H, Fulton D, Ganz T, Vogel H . The solution structure of human hepcidin, a peptide hormone with antimicrobial activity that is involved in iron uptake and hereditary hemochromatosis. J Biol Chem. 2002; 277(40):37597-603. DOI: 10.1074/jbc.M205305200. View

Nicolas G, Viatte L, Lou D, Bennoun M, Beaumont C, Kahn A . Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis. Nat Genet. 2003; 34(1):97-101. DOI: 10.1038/ng1150. View

Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen B . IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004; 113(9):1271-6. PMC: 398432. DOI: 10.1172/JCI20945. View

Nemeth E, Tuttle M, Powelson J, Vaughn M, Donovan A, Ward D . Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004; 306(5704):2090-3. DOI: 10.1126/science.1104742. View

Papanikolaou G, Pantopoulos K . Iron metabolism and toxicity. Toxicol Appl Pharmacol. 2005; 202(2):199-211. DOI: 10.1016/j.taap.2004.06.021. View

Rivera S, Nemeth E, Gabayan V, Lopez M, Farshidi D, Ganz T . Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-containing organs. Blood. 2005; 106(6):2196-9. PMC: 1895137. DOI: 10.1182/blood-2005-04-1766. View

Nemeth E, Preza G, Jung C, Kaplan J, Waring A, Ganz T . The N-terminus of hepcidin is essential for its interaction with ferroportin: structure-function study. Blood. 2005; 107(1):328-33. PMC: 1895343. DOI: 10.1182/blood-2005-05-2049. View

Khan F, Fisher M, Khakoo R . Association of hemochromatosis with infectious diseases: expanding spectrum. Int J Infect Dis. 2007; 11(6):482-7. DOI: 10.1016/j.ijid.2007.04.007. View

10.

Babitt J, Huang F, Xia Y, Sidis Y, Andrews N, Lin H . Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest. 2007; 117(7):1933-9. PMC: 1904317. DOI: 10.1172/JCI31342. View

11.

Yu P, Hong C, Sachidanandan C, Babitt J, Deng D, Hoyng S . Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol. 2007; 4(1):33-41. PMC: 2727650. DOI: 10.1038/nchembio.2007.54. View

12.

Miura K, Taura K, Kodama Y, Schnabl B, Brenner D . Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology. 2008; 48(5):1420-9. DOI: 10.1002/hep.22486. View

13.

Veronese F, Mero A . The impact of PEGylation on biological therapies. BioDrugs. 2008; 22(5):315-29. DOI: 10.2165/00063030-200822050-00004. View

14.

Andriopoulos Jr B, Corradini E, Xia Y, Faasse S, Chen S, Grgurevic L . BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet. 2009; 41(4):482-7. PMC: 2810136. DOI: 10.1038/ng.335. View

15.

Jordan J, Poppe L, Haniu M, Arvedson T, Syed R, Li V . Hepcidin revisited, disulfide connectivity, dynamics, and structure. J Biol Chem. 2009; 284(36):24155-67. PMC: 2782009. DOI: 10.1074/jbc.M109.017764. View

16.

Hashizume M, Uchiyama Y, Horai N, Tomosugi N, Mihara M . Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production. Rheumatol Int. 2009; 30(7):917-23. DOI: 10.1007/s00296-009-1075-4. View

17.

Sasu B, Cooke K, Arvedson T, Plewa C, Ellison A, Sheng J . Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood. 2010; 115(17):3616-24. DOI: 10.1182/blood-2009-09-245977. View

18.

Fatih N, Camberlein E, Island M, Corlu A, Abgueguen E, Detivaud L . Natural and synthetic STAT3 inhibitors reduce hepcidin expression in differentiated mouse hepatocytes expressing the active phosphorylated STAT3 form. J Mol Med (Berl). 2010; 88(5):477-86. DOI: 10.1007/s00109-009-0588-3. View

19.

Moran-Jimenez M, Mendez M, Santiago B, Rodriguez-Garcia M, Moreno-Carralero M, Sanchez-Lucio A . Hepcidin treatment in Hfe-/- mice diminishes plasma iron without affecting erythropoiesis. Eur J Clin Invest. 2010; 40(6):511-7. DOI: 10.1111/j.1365-2362.2010.02291.x. View

20.

Basaria S, Coviello A, Travison T, Storer T, Farwell W, Jette A . Adverse events associated with testosterone administration. N Engl J Med. 2010; 363(2):109-22. PMC: 3440621. DOI: 10.1056/NEJMoa1000485. View